Table 1 Patients and disease characteristics
Number of patients and spinal metastases | 32 and 54 |
Sex (F/M) | 11/21 |
Median age (range) | 68 (43–83 years) |
Median performance status (range) | 1 (0–2) |
Histology (%) | |
Lung | 2 (6.2%) |
Breast | 9 (28.1%) |
Prostate | 15 (46.9%) |
Others | 6 (18.8%) |
Median number of spinal metastases (range) | 1 (1–3) |
Pre-treatment MRI | 5 (15.6%) |
Pre-treatment PET-CT | 22 (68.8%) |
Pre-treatment combined radiological exams | 5 (15.6%) |
Vertebra (%) | |
Cervical | 7 (13.0%) |
Dorsal | 36 (66.7%) |
Lumbar | 11 (20.3%) |
Sacral | 0 |
Anatomical site (%) | |
Vertebral body | 27 (50%) |
Vertebral body + spinal process | 1 (1.9%) |
Vertebra body + peduncle | 8 (14.8%) |
Vertebral body + spinal process + peduncle | 4 (7.4%) |
Peduncle | 8 (14.8%) |
Spinal process | 4 (7.4%) |
Full vertebra | 2 (3.7%) |
Spinal Instability Neoplastic Score (SINS) | |
Median (range) | 5 |
0–6 | 22 (68.7%) |
7–12 | 10 (31.3%) |
Pre-treatment Visual Analogue Scale (VAS) | |
Median (range) | 0 (range 0–8) |
VAS at first follow-up | 0 (range 0–7) |
VAS at Post-treatment | |
Median (range) | 0 (range 0–7) |
Systemic therapy combined with SBRT (no; %) | |
None | 8 (25.0%) |
Hormone therapy | 16 (50%) |
Chemotherapy | 4 (12.5%) |
Target therapy | 0 |
Immunotherapy | 4 (12.5%) |